Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing. Drug-target interaction (DTI) models can rank vast numbers of drug-target pairs, but limited experimental capacity restricts testing to a small number of candidates.
We compared the bidirectional recommendations of 13 released systems across 711 molecular structures of FDA-approved